AF
HRTX icon

Advisornet Financial’s Heron Therapeutics HRTX Stock Holding History

Advisornet Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47 Hold
110
– – ﹤0.01% 2241
2026
Q1 		$88 Hold
110
– – ﹤0.01% 2205
2025
Q4 		$143 Hold
110
– – ﹤0.01% 2176
2025
Q3 		$139 Hold
110
– – ﹤0.01% 2175
2025
Q2 		$228 Hold
110
– – ﹤0.01% 2135
2025
Q1 		$242 Hold
110
– – ﹤0.01% 2059
2024
Q4 		$168 Hold
110
– – ﹤0.01% 1896
2024
Q3 		$219 Hold
110
– – ﹤0.01% 2114
2024
Q2 		$385 Hold
110
– – ﹤0.01% 1971
2024
Q1 		$305 Hold
110
– – ﹤0.01% 1927
2023
Q4 		$187 Hold
110
– – ﹤0.01% 2309
2023
Q3 		$113 Hold
110
– – ﹤0.01% 2205
2023
Q2 		$128 Hold
110
– – ﹤0.01% 2253
2023
Q1 		$166 Hold
110
– – ﹤0.01% 2275
2022
Q4 		$275 Hold
110
– – ﹤0.01% 2156
2022
Q3 		$0 Hold
110
– – ﹤0.01% 1931
2022
Q2 		$0 Hold
110
– – ﹤0.01% 1987
2022
Q1 		$1K Buy
+110
New +$805 ﹤0.01% 1888

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Advisornet Financial's HRTX Position: Q2 2026 in Review

Advisornet Financial held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 110 shares worth $47. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

Advisornet Financial first reported a position in HRTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $1K in Q1 2022. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Advisornet Financial held 110 shares of Heron Therapeutics worth $47 as of Q2 2026.
  • Advisornet Financial left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Advisornet Financial's portfolio in Q2 2026, its #2241 holding.
  • Advisornet Financial first reported a position in Heron Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Advisornet Financial's Heron Therapeutics position peaked at $1K in Q1 2022.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.